SCHEMBL18612967

SCHEMBL18612967

C=C(Cl)C(=C)OC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1721841 0.76
SCHEMBL2577652 0.73
SCHEMBL11229182 0.72
SCHEMBL14231385 0.71
SCHEMBL11806214 0.69
SCHEMBL11806218 0.69
SCHEMBL395499 0.67
SCHEMBL8119067 0.67
SCHEMBL21626792 0.67
SCHEMBL19312110 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4083032-A1 PD-L1 ANTAGONIST COMPOUND Adlai Nortye Biopharma Co., Ltd. (CN) 2022-11-02 EP disclosed
EP-3845534-A1 SALT FORM AND CRYSTAL FORM OF NOVEL AZATRICYCLIC COMPOUND AND USE THEREOF Betta Pharmaceuticals Co., Ltd (CN) 2021-07-07 EP disclosed
EP-2872491-B1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORP (US) 2021-05-05 EP disclosed
EP-3680236-A1 AROMATIC DERIVATIVE, PREPARATION METHOD FOR SAME, AND MEDICAL APPLICATIONS THEREOF Bioardis LLC (US) 2020-07-15 EP disclosed
US-10399963-B2 Substituted benzofuranyl and benzoxazolyl compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2019-09-03 US disclosed
EP-3508482-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF Nanjing Transthera Biosciences Co. Ltd. (CN) 2019-07-10 EP disclosed
WO-2019047826-A1 AROMATIC DERIVATIVE, PREPARATION METHOD FOR SAME, AND MEDICAL APPLICATIONS THEREOF 博奥阿迪斯生物科技公司 2019-03-14 WO disclosed
US-9938258-B2 Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2018-04-10 US disclosed
US-20170267685-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2017-09-21 US disclosed
US-20170066812-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2017-03-09 US disclosed